An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International

Roman‐Ulrich Müller(Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases), Ron T. Gansevoort(University Medical Center Groningen), Albert Ong(University of Sheffield), Tess Harris(Polycystic Kidney Disease Foundation), Roser Torrá(Universitat Autònoma de Barcelona), A. Lianne Messchendorp(University Medical Center Groningen), Patrick Guirchoun, Tom Nijenhuis(Radboud University Nijmegen), Ewout J. Hoorn(Erasmus MC), Olivier Devuyst(Cliniques Universitaires Saint-Luc), Giovambattista Capasso(Canon (Japan)), Franz Schaefer(Heidelberg University), John A. Sayer(Newcastle University), Aude Servais(Hôpital Necker-Enfants Malades), Henrik Birn(Aarhus University), Djalila Mekahli(KU Leuven), Stephen B. Walsh(University College London), Albertien M. van Eerde(Hospital Reina Sofía de Murcia), Nine V.A.M. Knoers(University Medical Center Groningen), Vladimı́r Tesař(Charles University), Émilie Cornec-Le Gall(Inserm), Yannick Le Meur(Université de Bretagne Occidentale), Uwe Korst

Nephrology Dialysis Transplantation

November 9, 2021

Cited by 135

|Kidney International|2021|2.5k

|Kidney International|2010|2.3k

|The Nephron journals/Nephron journals|2016|1.9k

|Journal of Hypertension|2016|1.4k

|The Lancet Global Health|2019|1.2k

Related Papers